Chimeric Therapeutics Limited (ASX:CHM)

Paul Hopper
Executive Chairman
Market Cap (AUD): 75.65M
Sector: Health Care
Last Trade (AUD): 0.39 +0.01 (+1.3%)
Tab Bar

1. about

Chimeric Therapeutics Limited (ASX:CHM) is developing ground-breaking CAR T cell therapies for solid tumors based on research at the City of Hope Cancer Centre in Los Angeles. The technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor targeting component of the CAR to reprogram T cells and is currently undergoing Phase 1 clinical trials at City of Hope in glioblastoma.

2. Business model

3. Strategy

4. Markets

5. Competition

6. History

7. Team

8. Financials

9. Risk